Close Menu

NEW YORK (GenomeWeb) – Sunnyvale, California-based InSilixa has received funding to develop a point-of-care rapid molecular diagnostic assay for oral human papillomavirus detection, the company announced today.

The $224,764 Phase I Small Business Innovation Research grant was awarded by the National Institutes of Health.

The assay is "a potential new tool to screen oral specimens such as saliva for cancer-causing HPV types and to risk stratify those persons found to be positive,” Gary Schoolnik, chief medical officer of InSilixa, said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.